Related Experiment Video
Updated: Sep 3, 2025
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Novel Endometrial Cancer Models Using Sensitive Metastasis Tracing for CXCR4-Targeted Therapy in Advanced Disease
Esperanza Medina-Gutiérrez1,2, María Virtudes Céspedes1, Alberto Gallardo3
1Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain.
Abstract:
Advanced endometrial cancer (EC) lacks therapy, thus, there is a need for novel treatment targets. CXCR4 overexpression is associated with a poor prognosis in several cancers, whereas its inhibition prevents metastases. We assessed CXCR4 expression in EC in women by using IHC. Orthotopic models were generated with transendometrial implantation of CXCR4-transduced EC cells. After in vitro evaluation of the CXCR4-targeted T22-GFP-H6 nanocarrier, subcutaneous EC models were used to study its uptake in tumor and normal organs. Of the women, 91% overexpressed CXCR4, making them candidates for CXCR4-targeted therapies. Thus, we developed CXCR4+ EC mouse models to improve metastagenesis compared to current models and to use them to develop novel CXCR4-targeted therapies for unresponsive EC. It showed enhanced dissemination, especially in the lungs and liver, and displayed 100% metastasis penetrance at all clinically relevant sites with anti-hVimentin IHC, improving detection sensitivity. Regarding the CXCR4-targeted nanocarrier, 60% accumulated in the SC tumor; therefore, selectively targeting CXCR4+ cancer cells, without toxicity in non-tumor organs. Our CXCR4+ EC models will allow testing of novel CXCR4-targeted drugs and development of nanomedicines derived from T22-GFP-H6 to deliver drugs to CXCR4+ cells in advanced EC. This novel approach provides a therapeutic option for women with metastatic, high risk or recurrent EC that have a dismal prognosis and lack effective therapies.
Insights
Advanced endometrial cancer (EC) has limited treatment options. Researchers identified CXCR4 overexpression in 91% of EC patients, suggesting it as a therapeutic target for novel CXCR4-targeted nanomedicines.
Area of Science:
- Oncology
- Nanomedicine
- Cancer Biology
Background:
- Advanced endometrial cancer (EC) presents a significant therapeutic challenge due to a lack of effective treatments.
- CXCR4 receptor overexpression is linked to poor prognosis and metastasis in various cancers, highlighting its potential as a therapeutic target.
Purpose of the Study:
- To investigate CXCR4 expression in endometrial cancer patients.
- To develop and validate novel CXCR4-positive (CXCR4+) EC mouse models for therapeutic development.
- To evaluate a CXCR4-targeted nanocarrier for drug delivery in EC.
Main Methods:
- Immunohistochemistry (IHC) was used to assess CXCR4 expression in human EC tissues.
- Orthotopic and subcutaneous EC mouse models were generated using CXCR4-transduced EC cells.
- In vitro and in vivo studies evaluated the efficacy and biodistribution of the T22-GFP-H6 nanocarrier targeting CXCR4.
Main Results:
- CXCR4 was overexpressed in 91% of human EC samples, identifying them as candidates for CXCR4-targeted therapies.
- Developed CXCR4+ EC mouse models demonstrated enhanced metastasis, particularly to the lungs and liver, with 100% penetrance.
- The CXCR4-targeted nanocarrier showed significant accumulation (60%) in subcutaneous tumors with no observed toxicity in normal organs.
Conclusions:
- CXCR4 is a promising therapeutic target for advanced and metastatic endometrial cancer.
- The developed CXCR4+ EC models are valuable tools for testing novel CXCR4-targeted drugs and nanomedicines.
- This approach offers a potential new therapeutic strategy for patients with advanced, high-risk, or recurrent EC lacking effective treatments.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014